Our mission: redefine diseases using patient transcriptomics data to uncover hidden drug targets
PROBLEM:
|
OUR SOLUTION:
|
HOW WE DO IT:
Unravel begins with patients, using their RNA to define each disease using molecular data. Our proprietary probabilistic network model of human health predicts drugs to restore a disease back to health, screening 40,000+ compunds in silico with 200x the hit rate of typical drug screens. Our unbiased screening platform further downselects hits that work in a whole organism, letting us ask clinically-relevant questions from the start. We then use these drugs to find new, hidden drug targets, validate them in the clinic, and develop new therapies.
The result: we decode patients' diseases to enable effective therapeutics, quickly and with lower development risk.
Unravel begins with patients, using their RNA to define each disease using molecular data. Our proprietary probabilistic network model of human health predicts drugs to restore a disease back to health, screening 40,000+ compunds in silico with 200x the hit rate of typical drug screens. Our unbiased screening platform further downselects hits that work in a whole organism, letting us ask clinically-relevant questions from the start. We then use these drugs to find new, hidden drug targets, validate them in the clinic, and develop new therapies.
The result: we decode patients' diseases to enable effective therapeutics, quickly and with lower development risk.
We can't do this alone.
|
We are committed to getting patients effective drugs the fastest way possible. We partner with companies, foundations, and researchers to amplify their strengths and datasets through cost-effective decision-making in the areas of target discovery, mechanism identification, drug optimization, and patient stratification for small molecules and biologics.
|